News for 'Sun Pharmaceuticals'

Regulatory woes torpedo PE/VC deals in e-pharma sector

Regulatory woes torpedo PE/VC deals in e-pharma sector

Rediff.com27 Jun 2023

With regulatory uncertainties clouding the future of online pharmacies, deals in the space are showing signs of slowdown, as also fresh investment from private-equity (PE) firms and venture capitalists (VCs). The data from Venture Intelligence shows so far in 2023 (as of June 13) there has been one deal with PE-VC funding. In 2022 there were four, a sharp fall from the 12, totalling $1,520 million, the sector had attracted in 2021.

Modi holds bilaterals with world leaders at BRICS summit

Modi holds bilaterals with world leaders at BRICS summit

Rediff.com24 Aug 2023

Modi held a "productive meeting" with his Ethiopian counterpart Abiy Ahmed Ali on a day when BRICS (Brazil, Russia, India, China and South Africa) leaders officially endorsed Ethiopia's entry into the bloc.

Major General S C N Jatar: An Unsung Hero

Major General S C N Jatar: An Unsung Hero

Rediff.com25 Oct 2023

Major General S C N Jatar, who passed into the ages on Monday night, thwarted anti-national forces at the peak of the Assam agitation. Colonel Anil A Athale (retd) salutes this officer and gentleman.

India's exports cross $800 bn in first 6 months of 2023

India's exports cross $800 bn in first 6 months of 2023

Rediff.com21 Aug 2023

A healthy growth in India's services segments has helped the country's total exports and imports of goods and services to cross the $800 billion mark during the first half of 2023, despite a slowdown in global demand, think tank GTRI said in a report on Monday. According to the analysis of the Global Trade Research Initiative (GTRI), exports of goods and services rose by 1.5 per cent to $385.4 billion during January-June this year, as against $379.5 billion in January-June 2022. Imports, however, dipped by 5.9 per cent to $415.5 billion during the six months of this year, as against $441.7 billion in January-June 2022.

India Inc braces for fallout of Russia-Ukraine crisis

India Inc braces for fallout of Russia-Ukraine crisis

Rediff.com23 Feb 2022

Stocks of Indian companies with exposure to Europe fell on Tuesday amid concerns about the impact on their sales in case the Russia-Ukraine crisis worsens and the US and its allies impose economic sanctions on Russia. While top conglomerates, including Reliance Industries, the Tata group, and Aditya Birla Group, said they did not have any significant exposure to Russia, executives of some of the oil and gas, pharmaceutical, and tea companies said they were monitoring the situation closely as they earned substantial income from the region. Russian President Vladimir Putin on Monday ordered troops into two breakaway regions of eastern Ukraine after announcing that Russia would recognise their independence.

Big pharma firms shift tack, look to bet on trade generics as volumes dip

Big pharma firms shift tack, look to bet on trade generics as volumes dip

Rediff.com7 Aug 2023

Trade generic drugs (medicines that are sold directly through distributors) are fast becoming a key segment for domestic pharma firms as volume growth slows in the overall market. Big companies like Cipla and Alkem have a significant presence in the segment but recently, players like Torrent Pharmaceuticals and Dr Reddy's Laboratories (DRL) have also entered this market. What is driving big pharma's focus on trade generics? The volume growth in the Indian Pharma Market (IPM) has come down from 5.6 per cent in FY16 to 0.1 per cent in FY23.

World Bank report warns of heatwaves beyond endurance in India

World Bank report warns of heatwaves beyond endurance in India

Rediff.com7 Dec 2022

Severe heatwaves, responsible for thousands of deaths across India over the last few decades, are increasing with alarming frequency and soon the country could become one of the first places in the world to experience heatwaves that break the human survivability limit, according to a new report.

Uzbek kids' death: Noida company loses manufacturing licence

Uzbek kids' death: Noida company loses manufacturing licence

Rediff.com23 Mar 2023

The manufacturing licence of Noida-based pharmaceutical firm Marion Biotech has been cancelled by the Uttar Pradesh authorities, according to officials.

Cabinet nods Rs 15,000 cr scheme for pharma sector

Cabinet nods Rs 15,000 cr scheme for pharma sector

Rediff.com24 Feb 2021

The government on Wednesday approved a production-linked incentive (PLI) scheme for the pharmaceutical sector, entailing an outlay of Rs 15,000 crore. The Union Cabinet, chaired by Prime Minister Narendra Modi, approved the scheme which will benefit domestic manufacturers, help create employment and is expected to contribute to the availability of a wider range of affordable medicines for consumers. The duration of the scheme would be from 2020-21 to 2028-29 and is expected to promote the production of high value products in the country and increase the value addition in exports, an official release said.

How BAD Is The Job Market?

How BAD Is The Job Market?

Rediff.com2 Aug 2023

More people working in India's technology industry have lost their jobs in the first six months of 2023 than in the corresponding period in 2022.

First nasal spray for treating Covid patients launched in India

First nasal spray for treating Covid patients launched in India

Rediff.com9 Feb 2022

The company claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virus.

Exports dip 10.3% in May; trade deficit at 5-month high

Exports dip 10.3% in May; trade deficit at 5-month high

Rediff.com15 Jun 2023

Exports declined for the fourth-consecutive month by 10.3 per cent year-on-year to $34.98 billion in May, while the trade deficit widened to a five-month high of $22.12 billion. According to the data released by the commerce ministry on Thursday, key export sectors recording negative growth include petroleum products, gems and jewellery, engineering goods, ready-made garments of all textiles and chemicals. Imports also declined 6.6 per cent, six-month in a row, to $57.1 billion against $61.13 billion in the same month last year, the data showed.

Centre to hold meet amid massive Covid spike in China, elsewhere

Centre to hold meet amid massive Covid spike in China, elsewhere

Rediff.com21 Dec 2022

The minister will review the COVID-19 situation at 11:30 am on Wednesday 'considering the international scenario', they said.

Chhattisgarh's 'Hamar Lab' is a medical game-changer

Chhattisgarh's 'Hamar Lab' is a medical game-changer

Rediff.com19 Jul 2022

Globally recognised organisations including the CDC, the Clinton Foundation, and domestic pharmaceutical and health care companies have sent their teams to visit the centres and study the concept, reports R Krishna Das.

'Investors should stay invested'

'Investors should stay invested'

Rediff.com14 Jul 2023

'Markets are not expensive; they are fairly priced.'

Om Puri: The Chronicler Of Cities On The Boil

Om Puri: The Chronicler Of Cities On The Boil

Rediff.com18 Oct 2023

'If it weren't for Om Puri, a whole range of our big city experiences wouldn't have found their honest representations on the screen.'

Cough syrup deaths: DCGI bans use of propylene glycol supplied by Delhi firm

Cough syrup deaths: DCGI bans use of propylene glycol supplied by Delhi firm

Rediff.com11 Mar 2023

Maya Chemtech India Pvt Ltd supplied propylene glycol used in Marion Biotech's cough syrups that were found to be "not of standard quality", according to the regulator.

Indian pharma cos get a shot in the arm in $12-bn Australian drug market

Indian pharma cos get a shot in the arm in $12-bn Australian drug market

Rediff.com29 Apr 2022

Indian drug firms get a shot in the arm in the $12 bn Australian drug market as the Therapeutic Goods Administration (TGA), Australia agrees to accelerate the drug approval process in that country for Indian players who already have an approved plant and product from one of the stringent regulatory authorities like US, EU or Canada. From current sales of $340 mn, the Indian firms can see a significant upside in sales; felt Dinesh Dua, former chairman of the Pharmaceutical Exports Promotion Council of India (Pharmexcil), and the MD of Nectar Lifesciences. He highlighted that only 12 percent of the Australian drug market is generic, as against 80-90 per cent in the US or EU. Of this $1.5 bn generic drug market in India, Indian companies have a small share.

India-US joint statement puts trade at heart of enhanced ties

India-US joint statement puts trade at heart of enhanced ties

Rediff.com23 Jun 2023

India and the US on Thursday said they are looking forward to the reconvening of the India-US Trade Policy Forum later this year to further enhance trade relationship and identify new areas for engagement.

Sensex closes 415 points higher; crosses 60K

Sensex closes 415 points higher; crosses 60K

Rediff.com6 Mar 2023

Among Sensex stocks, Tata Motors rose the most by 2.79 per cent. NTPC, Reliance Industries, Infosys, TCS, HDFC twins, Tata Motors, ITC, Power Grid and Bajaj Finserv were among the major gainers. Tata Steel fell the most by 1.22 per cent. L&T, Sun Pharmaceuticals, IndusInd Bank and Ultratech Cement were among the losers.

Reliance Takes Another Bite At Dairy

Reliance Takes Another Bite At Dairy

Rediff.com18 Apr 2023

This is the Mukesh Ambani-led company's second entry into the dairy segment and it will directly compete with Amul and Mother Dairy.

Sun Pharma's growth prospects look healthy; analysts positive on the stock

Sun Pharma's growth prospects look healthy; analysts positive on the stock

Rediff.com19 Jun 2023

Sun Pharmaceutical Industries (Sun Pharma) reported a turnaround in the January-March quarter of the 2022-23 financial year (Q4FY23), declaring a profit after tax (PAT) of Rs 1,984 crore versus a loss of Rs 2,277 crore in Q4FY22. However, that loss in FY22 was due to several exceptional one-time items -- with Rs 3,723.15 crore allocated to settlement of lawsuits in the US and other Exceptional Items adding up to Rs 3,935.75 crore. Adjusted for exceptional items, PAT in Q4FY22 amounts to Rs 2,155 crore, which is a year-on-year (YoY) growth of about 36 per cent.

'El Nino impact an immediate concern to markets'

'El Nino impact an immediate concern to markets'

Rediff.com4 Jul 2023

'Geopolitical risks and their impact on oil prices, if any, are another concern for global markets, particularly for India.'

5 more manufacturers to produce black fungus drug: Govt

5 more manufacturers to produce black fungus drug: Govt

Rediff.com21 May 2021

The Union health ministry on Friday said license has been given to five more manufacturers for production of Amphotericin-B, used in the treatment of black fungus, and they will start producing 1,11,000 vials of the drug per month from July.

Factors that will sustain Abbott outperformance

Factors that will sustain Abbott outperformance

Rediff.com22 Mar 2023

Abbott India outperformed the Indian pharmaceutical market (IPM) with a year-on-year (YoY) growth of 23 per cent in February. The domestic market grew at a robust 20 per cent on a low base, primarily led by volume growth and price hikes. Abbott continued to outperform the sector in the anti-diabetic space with a growth of 20 per cent and key brands such as Thyronorm (hypothyroidism), biliary agent Udiliv, insulin Ryzodeg posted robust growth.

Watch Live! All the action in Parliament

Watch Live! All the action in Parliament

Rediff.com2 Dec 2021

On Day 4 of Winter Session, Lok Sabha will discuss the 'COVID-19 pandemic and various aspects related to it'.

Ethical Code to keep doctor, drugmaker nexus at bay not mandatory yet

Ethical Code to keep doctor, drugmaker nexus at bay not mandatory yet

Rediff.com22 Aug 2022

'Gift-giving' - from free dinners and drug samples to promotional merchandise - seems to be driving drugmakers' marketing - a marketing prescription deeply entrenched in the industry. This is a well-oiled racket that sees pharmaceutical (pharma) companies 'gifting' doctors to push their respective drugs under the guise of marketing. But is there a cure in sight to end this unhealthy alliance? The recent controversy following the income-tax raids on Bengaluru-based drugmaker Micro Labs, makers of popular paracetamol brand Dolo-650, has brought this to the fore, again.

Barsu refinery: People must be taken into confidence, says Uddhav

Barsu refinery: People must be taken into confidence, says Uddhav

Rediff.com28 Apr 2023

Thackeray, whose Maha Vikas Aghadi government fell after a rebellion in June last year by his cabinet colleague Eknath Shinde, who went on to become CM, also warned he would extract revenge for his ouster.

How India Can Rival China As Production Platform

How India Can Rival China As Production Platform

Rediff.com28 Jul 2023

We have the workforce, now we need to ensure that we take full advantage of game-changing technologies and geopolitical openings, suggests Jayant Sinha, chairman, Parliament's Standing Committee on Finance.

Why Zydus is likely to continue with its outperformance

Why Zydus is likely to continue with its outperformance

Rediff.com31 Mar 2023

Even as most of its large-cap pharmaceutical peers have struggled to stay above water on the returns front, Zydus Lifesciences has been one of the big outperformers within the sector over the past year with a return of over 30 per cent. The gains have come on the back of multiple triggers such as the scaling up of new product launches in the US market, clearance for its Moraiya (Gujarat) facility and steady performance in the domestic market. Though it has been the top pharma gainer in the 2022-23 financial year (FY23), brokerages continue to maintain their 'buy' stance, given the strong visibility in the US market.

Over one-third Nifty50 stocks look weak on charts. Time to be cautious?

Over one-third Nifty50 stocks look weak on charts. Time to be cautious?

Rediff.com30 May 2023

The domestic benchmark indices - the S&P BSE Sensex and the National Stock Exchange Nifty50 - had lost close to 1.5 per cent in three days recently before gaining slightly. Notwithstanding weakness and volatility, the Nifty50 has managed to hold on to the 18,000 mark, while the Sensex has managed to stay above the 61,000 level. The performance of the stocks that comprise these front-line indices remains polarised.

Central panel to study WHO report on deaths linked to Indian syrups

Central panel to study WHO report on deaths linked to Indian syrups

Rediff.com12 Oct 2022

They said after examining and analysing the adverse event reports, causal relationship and all related details shared by or to be shared by the WHO, the committee will advise and recommend further course of action to the Drugs Controller General of India (DCGI).

'Technology' appears 44 times in Modi-Biden statement, up from 5 three years ago

'Technology' appears 44 times in Modi-Biden statement, up from 5 three years ago

Rediff.com24 Jun 2023

From the seas to the stars, this partnership will now be deepened by the defining role of technology, the statement said.

Three scientists share Nobel Prize for 'Click Chemistry'

Three scientists share Nobel Prize for 'Click Chemistry'

Rediff.com5 Oct 2022

The Royal Swedish Academy of Sciences on Wednesday awarded the Nobel Prize in Chemistry 2022 to Carolyn R Bertozzi, Morten Meldal and K Barry Sharpless.

India's personal data protection bill may threaten innovation, growth: USTR

India's personal data protection bill may threaten innovation, growth: USTR

Rediff.com29 Apr 2022

The US on Thursday raised concerns over India's Personal Data Protection (PDP) Bill and draft non-personal data governance framework, claiming these could potentially threaten innovation and economic growth. In its latest 'Special 301' Report, the US Trade Representative (USTR) kept India on the priority watch list, maintaining the country remains one of the world's most challenging major economies with respect to protection and enforcement of intellectual property (IP). In December 2021, a joint parliamentary committee released a report recommending changes to the PDP Bill, 2019, that could undermine important IP protections in India.

Rupee @ 80: Forex deficit to hurt India Inc's margins

Rupee @ 80: Forex deficit to hurt India Inc's margins

Rediff.com28 Jul 2022

The rupee breached the 80-mark against the dollar on Tuesday. The steady depreciation in the value of the rupee against the US dollar is likely to prove expensive for corporate India. The listed companies' revenue expenses in foreign currency or imports exceed their export revenues or revenue earnings in forex. In their latest financial year, BSE500 companies, excluding banks and non-banking finance companies and insurance (BFSI), reported combined forex expenses of Rs 12.31 trillion against forex earnings of around Rs 10 trillion.

India Needs Insulation From Grey Rhinos

India Needs Insulation From Grey Rhinos

Rediff.com27 Jun 2023

India must be prepared to deal with climate disasters, geopolitical confrontations, and social strife linked to global events, asserts Jayant Sinha, chairman of Parliament's Standing Committee on Finance.

Govt ramps up Remdesivir production to 74 lakh vials

Govt ramps up Remdesivir production to 74 lakh vials

Rediff.com23 Apr 2021

The Union home ministry said several steps have been taken to augment the production and supply of Remdesivir injections from 38.80 lakh units per month to 74 lakh units per month by early next month, and asked the states to ensure its seamless supply and transport.

Centre seeks info from embassy on Iran's bar on rice, tea imports

Centre seeks info from embassy on Iran's bar on rice, tea imports

Rediff.com8 Dec 2022

The department of commerce has urged the agriculture ministry as well as the diplomatic mission in Tehran to apprise it of details as to why Iranian buyers have stopped import of rice and tea from India, a senior government official said. Exporters said that exports of items such as high quality tea and rice have stopped since last week. As of now, there has been no confirmation from the authorities and the response from the embassy in Tehran is also taking time, they said.

Exports rise to record high of $418 bn in FY22

Exports rise to record high of $418 bn in FY22

Rediff.com3 Apr 2022

India's merchandise exports spurted to a record high of $418 billion in the 2021-22 fiscal on higher shipments of petroleum products, engineering goods, gem and jewellery and chemicals, according to official data released on Sunday. Outbound shipments touched an all-time high of $40 billion in a month in March 2022, Commerce and Industry Minister Piyush Goyal told reporters. Exports stood at $34 billion in March 2021.